Cargando…
Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines
Uveal melanoma is the most common primary malignancy of the eye in adults. Despite significant improvements in treatment of the primary tumor, to date none of these therapies prevent metastatic disease or improve overall survival. We are exploring immunotherapeutic options for metastatic uveal melan...
Autores principales: | Kittler, Julia M., Sommer, Jonas, Fischer, Anika, Britting, Sabine, Karg, Margarete M., Bock, Barbara, Atreya, Imke, Heindl, Ludwig M., Mackensen, Andreas, Bosch, Jacobus J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442993/ https://www.ncbi.nlm.nih.gov/pubmed/30956760 http://dx.doi.org/10.18632/oncotarget.26737 |
Ejemplares similares
-
Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma
por: Goesmann, Lara, et al.
Publicado: (2023) -
Dendritic Cells Utilize the Evolutionarily Conserved WASH and Retromer Complexes to Promote MHCII Recycling and Helper T Cell Priming
por: Graham, Daniel B., et al.
Publicado: (2014) -
Monomeric agonist peptide/MHCII complexes activate T‐cells in an autonomous fashion
por: Platzer, René, et al.
Publicado: (2023) -
Gr1(−/low)CD11b(−/low)MHCII(+) myeloid cells boost T cell anti‐tumor efficacy
por: Payne, Kyle K., et al.
Publicado: (2018) -
Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation
por: Yang, Heeyoung, et al.
Publicado: (2014)